Table 2.

Serum concentrations of 5α-androstane-3α,17β-diol glucuronide, sex steroid hormones, and sex hormone binding globulin, before and after finasteride treatment, among treatment-compliant men in the Prostate Cancer Prevention Trial finasteride arm

NMedian (IQRa)Mean (SD)
3α-dG, ng/mLb
 Baseline1,2475.7 (3.9,8.0)6.8 (5.1)
 Posttreatment1,2471.5 (1.0,2.1)1.9 (1.7)
 Absolute differencec,d1,247−4.1 (−6.1,−2.4)−4.9 (4.7)
 Absolute difference, baseline adjustedc,d1,247−5.2 (−5.6,−4.7)−4.9 (1.5)
 % Differencec,e1,247−73.8 (−81.5,−62.6)−67.1 (32.6)
Testosterone, ng/dL
 Baseline1,246361 (285,448)381 (138)
 Posttreatment1,246398 (316,496)421 (157)
 Absolute differencec,d1,24637.0 (−31.0,103.0)39.9 (121.0)
 Absolute difference, baseline adjustedc,d1,24629.6 (−33.6,96.4)39.9 (116.5)
 % Differencec,e1,24610.1 (−8.1,31.7)14.7 (36.1)
Free testosterone, ng/dL
 Baseline1,2468.4 (6.8,10.0)8.7 (2.7)
 Posttreatment1,2469.1 (7.3,10.9)9.4 (3.0)
 Absolute differencec,d1,2460.7 (−1.00,2.2)0.7 (2.7)
 Absolute difference, baseline adjustedc,d1,2460.5 (−0.9,2.0)0.7 (2.5)
 % Differencec,e1,2467.5 (−10.4,29.4)12.5 (36.8)
Estrone, pg/mL
 Baseline1,22744.4 (35.8,55.2)46.5 (15.6)
 Posttreatment1,22749.2 (39.9,59.8)51.8 (17.0)
 Absolute differencec,d1,2274.7 (−3.3,13.2)5.2 (15.2)
 Absolute difference, baseline adjustedc,d1,2273.7 (−3.8,11.8)5.2 (14.0)
 % Differencec,e1,22711.2 (−7.2,35.5)16.5 (35.3)
Estradiol, pg/mL
 Baseline1,23633.5 (26.7,40.5)34.6 (11.7)
 Posttreatment1,23635.6 (29.3,43.3)37.4 (12.4)
 Absolute differencec,d1,2362.6 (−3.4,8.1)2.7 (11.5)
 Absolute difference, baseline adjustedc,d1,2361.9 (−3.4,7.4)2.7 (10.4)
 % Differencec,e1,2367.5 (−8.8,28.1)11.7 (32.4)
Free estradiol, pg/mL
 Baseline1,2360.9 (0.7,1.1)0.9 (0.3)
 Posttreatment1,2360.9 (0.8,1.2)1.0 (0.3)
 Absolute differencec,d1,2360.0 (−0.1,0.2)0.1 (0.3)
 Absolute difference, baseline adjustedc,d1,2360.0 (−0.1,0.2)0.1 (0.3)
 % Differencec,e1,2365.3 (−10.7,26.1)9.6 (31.8)
Sex hormone binding globulin, nmol/L
 Baseline1,24736.0 (28.0,45.7)38.5 (16.2)
 Posttreatment1,24738.3 (29.4,48.7)40.8 (16.3)
 Absolute differencec,d1,2472.0 (−2.7,6.8)2.3 (10.4)
 Absolute difference, baseline adjustedc,d1,2471.3 (−3.1,6.4)2.3 (9.9)
 % Differencec,e1,2476.0 (−7.1,20.4)8.9 (25.7)
  • aInterquartile range.

  • b5α-androstane-3α,17β-diol glucuronide.

  • cP < 0.0001.

  • dPosttreatment−baseline.

  • e100 × (posttreatment−baseline)/baseline.